Abstract
Activated monocytes or macrophages can release soluble cytotoxic molecules capable of lysing tumour cells in vitro1–6 and thus represent an important component of the host defence mechanisms against malignancy. The recent availability of pure recombinant or natural human lymphokines and monokines and their respective polyclonal or monoclonal antibodies now makes it possible to dissect the interactions of these factors in the induction and performance of the cytotoxic event by the monocytes. Our studies indicate that pretreatment of monocytes with α-IFN or γ-IFN, and also interleukin (IL)-l or tumour necrosis factor (TNF) results in enhanced monocyte cytotoxicity. Although all these substances induce the production of IL-1 by monocytes, TNF mediates the enhanced cytotoxicity induced in monocytes by γ-IFN, IL-1 and, in an autocrine manner, by TNF itself. Neither TNF, IL-1, γ-IFN nor α-IFN mediate spontaneous monocyte cytotoxicity or that induced by α-IFN. Our studies thus reveal new interactions between the two monokines IL-1 and TNF and provide a dual role for TNF, as immunomodulator and mediator of monocyte cytotoxicity induced by certain specific lymphokine and monokine molecules.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Matthews, N. Immunology 44, 135–142 (1981).
Cameron, D. J. J. reticuloendothel. Soc. 32, 247–256 (1982).
Reidarson, T. H., Levy, W. III, Klostergaard, J. & Granger, G. A. J. natn. Cancer Inst. 69, 879–887 (1982).
Adams, D. O. & Nathan, C. F. Immun. Today 4, 166–170 (1983).
Sone, S., Tachibana, K., Ishii, K., Ogawara, M. & Tsubura, E. Cancer Res. 44, 646–651 (1984).
McKinnon, K. P., Chen, A. R., Argov, S., Love, B. & Koren, H. S. Immunobiology 171, 26–44 (1986).
Colotta, F., Peri, G., Villa, A. & Mantovani, A. J. Immun. 132, 936–944 (1984).
Ziegler-Heitbrock, H. W. L. & Reithmuller, G. J. natn. Cancer Inst. 72, 23–29 (1984).
Koren, H. S. & Herberman, R. B. J. Leuk. Biol. 38, 441–445 (1985).
Cameron, D. J. & Churchill, W. H. J. Immun. 124, 708–712 (1980).
Peri, G., Polentarutti, N., Sessa, C., Mangioni, C. & Mantovani, A. Int. J. Cancer 28, 143–152 (1981).
Herberman, R. B. et al. Cell Immun. 67, 160–167 (1982).
Le, J. et al. J. Immun. 131, 2821–2826 (1983).
Blasi, E., Herberman, R. B. & Varesio, L. J. Immun. 132, 3226–3228 (1984).
Celada, A., Gray, P. W., Rinderknecht, E. & Schreiber, R. D. J. exp. Med. 60, 55–74 (1984).
Orchansky, P., Rubenstein, M. & Fischer, D. G. J. Immun. 136, 169–173 (1986).
Onozaki, K., Matsushima, K., Kleinerman, E. S., Saito, T. & Oppenheim, J. J. J. Immun. 135, 314–320 (1985).
Oppenheim, J. J. & Gery, I. Immun. Today 125, 113–119 (1982).
Herman, J., Kew, M. C. & Rabson, A. Cancer Immun. Immunother. 16, 182–185 (1984).
Wallis, R. S., Fujiwara, H. & Ellner, J. J. J. Immun. 136, 193–196 (1986).
Arenzana-Seisdedos, F., Virelizier, J. L. & Fiers, W. J. Immun. 134, 2444–2448 (1985).
Haq, A. U., Rinehart, J. J. & Maca, R. D. J. Leuk. Biol. 38, 735–746 (1985).
Candler, R. V., Rouse, B. T. & Moore, R. N. J. Interferon Res. 5, 179–189 (1985).
Roberts, N. J., Douglas, R. G., Simons, R. L. & Diamond, M. E. J. Immun. 123, 446–450 (1980).
Saksela, E., Virtanen, I., Hovi, T., Secher, D. S. & Cantell, K. Prog. med. Virol. 30, 78–86 (1984).
Dinarello, C. A. J. clin. Immun. 5, 287–297 (1985).
Carswell, E. A. et al. Proc. natn. Acad. Sci. U.S.A. 72, 3666–3670 (1975).
Kelker, H. C. et al. Int. J. Cancer 36, 69–73 (1985).
Chen, A. R., McKinnon, K. P. & Koren, H. S. J. Immun. 135, 3978–3987 (1985).
Kildahl-Andersen, O., Espevik, T. & Nissen-Meyer, J. Cell. Immun. 95, 392–406 (1985).
Staehelin, T., Hobbs, D. S., Kung, H.-F., Lai, C. Y. & Pestka, S. J. biol. Chem. 256, 9750–9754 (1981).
Gray, P. W. et al. Nature 295 503–508 (1982).
Rosenwasser, L. & Dinarello, C. Cell Immun. 63, 134–142 (1981).
Pennica, D. et al. Nature 312 724–729 (1984).
Boyum, A. Scand, J. clin. Lab. Invest. 21, Suppl. 97, 77–89 (1968).
Kaye, J. & Janeway, C. A., Jr Lymphokine Res. 3, 175–182 (1984).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Philip, R., Epstein, L. Tumour necrosis factor as immunomodulator and mediator of monocyte cytotoxicity induced by itself, γ-interferon and interleukin-1. Nature 323, 86–89 (1986). https://doi.org/10.1038/323086a0
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/323086a0
This article is cited by
-
Anti-inflammatory Effect of Curcuma longa and Allium hookeri Co-treatment via NF-κB and COX-2 Pathways
Scientific Reports (2020)
-
Innate, adaptive, and cell-autonomous immunity against Toxoplasma gondii infection
Experimental & Molecular Medicine (2019)
-
The meteorology of cytokine storms, and the clinical usefulness of this knowledge
Seminars in Immunopathology (2017)
-
Psoriatic arthritis is associated with increased arterial stiffness in the absence of known cardiovascular risk factors: a case control study
Clinical Rheumatology (2012)
-
Inflammation driven by tumour-specific Th1 cells protects against B-cell cancer
Nature Communications (2011)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.